Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia
Withdrawn before enrolling · Phase 2
Conditions studied: Lymphoma
In brief
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well alemtuzumab works in treating patients with Waldenstrom's macroglobulinemia.
Key facts
- Study ID
- NCT00081068
- Run by
- Jonsson Comprehensive Cancer Center
- People needed
- 0
- Starts
- 2004-01-01
- Last updated by the study team
- 2013-01-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Jonsson Comprehensive Cancer Center at UCLA — Los Angeles, California, United States
- Rocky Mountain Cancer Centers - Denver Midtown — Denver, Colorado, United States
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
- Greenebaum Cancer Center at University of Maryland Medical Center — Baltimore, Maryland, United States
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Long Island Jewish Medical Center — New Hyde Park, New York, United States
- Herbert Irving Comprehensive Cancer Center at Columbia University — New York, New York, United States
- Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
- Peter MacCallum Cancer Centre — East Melbourne, Victoria, Australia
- McMaster Children's Hospital at Hamilton Health Sciences — Hamilton, Ontario, Canada
- Princess Margaret Hospital — Toronto, Ontario, Canada
- Centre Hospitalier Lens — Lens, France
- Saint Bartholomew's Hospital — London, England, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.